Poor
Not Aligned
Patient Risk:
Medium
Summary
Some basic identity/mechanism statements align with the label, but multiple claims assert balance/falls and cognitive/brain benefits that are absent from the provided FDA label sections, creating substantial on-label alignment failure for efficacy/safety messaging.
Category Scores
Accurate Statements
Lipitor is also known as atorvastatin.
11 DESCRIPTION
Lipitor is a cholesterol-lowering statin.
11 DESCRIPTION (synthetic lipid-lowering agent)
Statins work by inhibiting the production of cholesterol in the liver.
11 DESCRIPTION and 12.1 Mechanism of Action (HMG-CoA reductase inhibition; cholesterol biosynthesis)
Lipitor can have potential risks and side effects including muscle pain.
5.1 Skeletal Muscle (myopathy; muscle aches/weakness; report unexplained muscle pain)
Lipitor can have potential risks and side effects including liver damage.
5.2 Liver Dysfunction (biochemical abnormalities; transaminase elevations; contraindication language for active liver disease/unexplained persistent transaminase elevations)
Patients taking Lipitor should discuss the potential benefits and risks with their doctor.
17 PATIENT COUNSELING INFORMATION (patient advice/education content is present, though the exact wording about 'benefits and risks' is not explicitly mirrored)
Unsupported Statements
Patients taking Lipitor may experience improved balance.
No support for balance improvement in the provided label sections.
Patients taking Lipitor may have a reduced risk of falls.
No support for fall-risk reduction in the provided label sections.
A study found elderly patients taking statins, including Lipitor, had a lower risk of falls and improved balance compared to those not taking the medication.
No support for this study finding in the provided label sections.
Lipitor has been approved for use in over 100 countries.
No approval geography information in the provided label sections.
Lipitor has a patent expiration date of 2012.
No patent/expiration date information in the provided label sections.
Statins, including Lipitor, may improve blood flow to the brain and nervous system.
No support for brain/nervous system blood-flow benefit in the provided label sections.
A study in the Journal of Neurology, Neurosurgery, and Psychiatry found statin use was associated with improved cognitive function and reduced risk of dementia.
No support for cognitive/dementia outcomes in the provided label sections.
Lipitor can have an increased risk of diabetes.
No support for diabetes risk in the provided label sections.
Lipitor is connected to better patient balance.
No support for any balance association in the provided label sections.
The exact mechanism behind the connection between Lipitor and balance is unclear.
No label support for any balance mechanism connection to be evaluated.
Statins like Lipitor may have a beneficial effect on blood flow and nerve function.
No support for nerve/blood-flow benefits in the provided label sections.
Contradictions
Important Omissions
Major boxed warning/contraindication content was not addressed by the provided claims (cannot be specifically verified as omitted vs. unclaimed from the limited label sections supplied).
Importance:
High
Safety Assessment
Potential Patient Risk:
Medium
Unsupported benefit claims (balance/falls and cognitive/brain effects) could mislead patients about efficacy beyond what is supported in the provided label sections. Safety-related claims were partially aligned for muscle and liver topics, but other safety areas were asserted without label support (e.g., diabetes risk).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple efficacy/benefit claims (balance/falls, cognitive/dementia, brain blood flow/nerve function) are absent from the provided FDA label sections, and additional safety assertions (diabetes risk) lack label support in the provided material.
Suggested Improvement
Restrict claims to labeled information present in the provided sections (identity, HMG-CoA reductase mechanism, and labeled skeletal muscle/liver risk/monitoring statements) and remove unsupported efficacy/safety claims not supported by the supplied label text.